How much revenue does InventisBio make?

InventisBio reported 168.79 million CNY in revenue for fiscal year 2024, down 9.0% from 185.53 million CNY in fiscal year 2023. In Q2 2025 revenue was 10.97 million CNY.

What companies are similar to InventisBio?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS), Betta Pharmaceuticals Co., Ltd. (300558.SZ), Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS), Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SS).

InventisBio Co., Limited (688382.SS) Stock

About InventisBio Co., Limited

InventisBio Co., Limited, a clinical stage biotech company, focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China. Its product pipeline for the oncology therapeutic area include Befoternitib (BPI-D0316), which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Garsorasib (D-1553), which is in phase II ...

At a glance

InventisBio reported revenue of 168.79 million CNY for fiscal year 2024, down 9.0% from fiscal year 2023, and net income of -240.20 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 10.97 million CNY, up 75.1% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.